{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T13:32:04Z","timestamp":1695994324457},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.vaccine.2011.12.067","type":"journal-article","created":{"date-parts":[[2011,12,30]],"date-time":"2011-12-30T20:37:32Z","timestamp":1325277452000},"page":"1357-1363","source":"Crossref","is-referenced-by-count":11,"title":["Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection"],"prefix":"10.1016","volume":"30","author":[{"given":"S.A.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Alawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Doro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.L.","family":"Henriquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Nok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.B.I.","family":"Alawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Alsaadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.B.","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.C.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.12.067_bib0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/0974-777X.68528","article-title":"Human immunodeficiency virus and leishmaniasis","volume":"2","author":"Ezra","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0010","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1016\/j.vaccine.2009.02.079","article-title":"Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection","volume":"27","author":"Goto","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/0974-777X.62883","article-title":"Treatment of visceral leishmaniasis","volume":"2","author":"Moore","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/0974-777X.62881","article-title":"Leishmaniasis vaccine: where are we today?","volume":"2","author":"Kedzierski","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0025","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2005.07.001","article-title":"Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals","volume":"23","author":"Gradoni","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0030","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.vaccine.2008.01.026","article-title":"Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f+MPL-SE vaccine to treat canine visceral leishmaniasis","volume":"26","author":"Miret","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0035","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.vaccine.2010.02.089","article-title":"Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.2","volume":"28","author":"Trigo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0040","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1645\/GE-2360.1","article-title":"Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection","volume":"96","author":"Henriquez","year":"2010","journal-title":"J Parasitol"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0045","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1016\/j.vaccine.2007.03.014","article-title":"DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection","volume":"25","author":"Carter","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0110","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1093\/nar\/gkg500","article-title":"Multiple sequence alignment with the Clustal series of programs","volume":"31","author":"Chenna","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0050","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.vaccine.2008.12.053","article-title":"KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major","volume":"27","author":"Bhaumik","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0055","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.parint.2009.11.003","article-title":"Comparative in vivo expression of amastigote up regulated Leishmania genes in three different forms of Leishmaniasis","volume":"59","author":"Sharma","year":"2010","journal-title":"Parasitol Int"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1471-2164-9-255","article-title":"Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species","volume":"9","author":"Rochette","year":"2008","journal-title":"BMC Genomics"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00430-010-0156-z","article-title":"Brombacher F.CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation","volume":"199","author":"H\u00fcnig","year":"2010","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0075","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1002\/1521-4141(200111)31:11<3255::AID-IMMU3255>3.0.CO;2-J","article-title":"IL-13 gene-deficient mice are susceptible to cutaneous L. mexicana infection","volume":"31","author":"Sosa","year":"2001","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2011.12.067_bib0080","doi-asserted-by":"crossref","first-page":"e930","DOI":"10.1371\/journal.pntd.0000930","article-title":"BALB\/c mice deficient in CD4 T cell IL-4R\u03b1 expression control Leishmania mexicana load although female but not male mice develop a healer phenotype","volume":"4","author":"Bryson","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0085","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/IAI.73.2.812-819.2005","article-title":"Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis","volume":"73","author":"Aguilar-Be","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0165-2478(98)00131-X","article-title":"Immune effector mechanism in parasitic infections","volume":"65","author":"Liew","year":"1999","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0095","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s001090050230","article-title":"Progressive disease or protective immunity to Leishmania major infection: the result of a network of stimulatory and inhibitory interactions","volume":"76","author":"Etges","year":"1998","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0100","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1086\/374783","article-title":"Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines","volume":"187","author":"Daneshvar","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.067_bib0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-0556-2-17","article-title":"DNA vaccines: designing strategies against parasitic infections","volume":"2","author":"Ivory","year":"2004","journal-title":"Genet Vaccines Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11020056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11020056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T11:22:35Z","timestamp":1543317755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11020056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0264410X11020056"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}